Elizabeth Woodruff, PhD, MA

Education
PhD (2017) in Neuroscience, University of Colorado, Boulder
MA (2013) in Psychology, University of Colorado, Boulder

Contact
Research Complex 2
12700 East 19th Avenue
Room 3400A, MS 8613
Aurora, CO 80045

Phone: (303) 724-0442
Fax: (303) 724-3512

Research Interests

• In vivo modeling and preclinical experimental design, management, and analysis
• Experiment design, execution, data analysis, and publication of experimental findings
• Several molecular and behavioral bioassays as well as in vivo and in vitro laboratory research techniques
• Primary research report/manuscript peer review (please see “Community Involvement” below)
• Curriculum development and teaching at the undergraduate and graduate level
• Mentorship and training
• Written and verbal communication skills, including public speaking and data presentation
• Use of statistical software (SPSS, Prism, Chronolab, StatView), Microsoft Office (Word, Excel,PowerPoint), graphing software (Prism, Kaleidagraph)

Full List of Publications

Recent Publications

1. Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Lin S, Villagomez FR, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Chuong EB, Bitler BG. EHMT1/2 inhibition promotes regression of therapy-resistant ovarian cancer tumors in a CD8 T cell-dependent manner. Mol Cancer Res. 2024 Aug 13;. doi: 10.1158/1541-7786.MCR-24-0067. [Epub ahead of print] PubMed PMID: 39136655.
2. Iwanaga R, Yamamoto TM, Gomez K, Nguyen LL, Woodruff ER, Post MD, Mikeska RG, Danis E, Danhorn T, Boorgula MP, Mitra SS, Marjon NA, Bitler BG, Brubaker LW. Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma. Cancer Res Commun. 2024 Aug 1;4(8):1919-1932. doi: 10.1158/2767-9764.CRC-24-0027. PubMed PMID: 38984891; PubMed Central PMCID: PMC11298703.
3. Villagomez FR, Lang J, Rosario FJ, Nunez-Avellaneda D, Webb P, Neville M, Woodruff ER, Bitler BG. Claudin-4 Modulates Autophagy via SLC1A5/LAT1 as a Mechanism to Regulate Micronuclei. Cancer Res Commun. 2024 Jul 1;4(7):1625-1642. doi: 10.1158/2767-9764.CRC-24-0240. PubMed PMID: 38867360; PubMed Central PMCID: PMC11218812.
4. Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Cocozaki A, Chuong EB, Bitler BG. Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation. Mol Cancer Ther. 2024 Jun 12;:OF1-OF16. doi: 10.1158/1535-7163.MCT-23-0613. [Epub ahead of print] PubMed PMID: 38863225.
5. Crump LS, Floyd JL, Kuo LW, Post MD, Bickerdike M, O'Neill K, Sompel K, Jordan KR, Corr BR, Marjon N, Woodruff ER, Richer JK, Bitler BG. Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression. Cancer Res Commun. 2024 Mar 18;4(3):822-833. doi: 10.1158/2767-9764.CRC-23-0513. PubMed PMID: 38451784; PubMed Central PMCID: PMC10946310.
6. Greenwood A, Woodruff ER, Nguyen C, Piper C, Clauset A, Brubaker LW, Behbakht K, Bitler BG. Early Ovarian Cancer Detection in the Age of Fallopian Tube Precursors: A Systematic Review. Obstet Gynecol. 2024 Mar 1;143(3):e63-e77. doi: 10.1097/AOG.0000000000005496. Epub 2024 Jan 4. PubMed PMID: 38176019; PubMed Central PMCID: PMC10922166.
7. Bapat J, Yamamoto TM, Woodruff ER, Qamar L, Mikeska RG, Aird KM, Watson ZL, Brubaker LW, Bitler BG. CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR. Cancer Gene Ther. 2024 Feb;31(2):300-310. doi: 10.1038/s41417-023-00703-1. Epub 2023 Nov 29. PubMed PMID: 38030811; PubMed Central PMCID: PMC10874890.
8. Brubaker LW, Backos DS, Nguyen VT, Reigan P, Yamamoto TM, Woodruff ER, Iwanaga R, Wempe MF, Kumar V, Persenaire C, Watson ZL, Bitler BG. Novel chromobox 2 inhibitory peptide decreases tumor progression. Expert Opin Ther Targets. 2023 Apr-May;27(4-5):361-371. doi: 10.1080/14728222.2023.2218614. Epub 2023 May 27. PubMed PMID: 37243607.
9. Sanders BE, Yamamoto TM, McMellen A, Woodruff ER, Berning A, Post MD, Bitler BG. Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma. Mol Cancer Ther. 2022 Aug 2;21(8):1285-1295. doi: 10.1158/1535-7163.MCT-21-0682. PubMed PMID: 35587258; PubMed Central PMCID: PMC9357222.
10. Yamamoto TM, Webb PG, Davis DM, Baumgartner HK, Woodruff ER, Guntupalli SR, Neville M, Behbakht K, Bitler BG. Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. Mol Cancer Ther. 2022 Apr 1;21(4):647-657. doi: 10.1158/1535-7163.MCT-21-0827. PubMed PMID: 35373300; PubMed Central PMCID: PMC8988515.